Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience

Takayuki Katsuno, Takenori Ozaki, Hangsoo Kim, Noritoshi Kato, Yasuhiro Suzuki, Shinichi Akiyama, Takuji Ishimoto, Tomoki Kosugi, Naotake Tsuboi, Yasuhiko Ito, Shoichi Maruyama

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

To date, a recognized treatment for refractory membranous nephropathy (MN) has not been established. Recently, several reports have indicated the efficacy of rituximab as a novel treatment option. However, only a few published accounts exist of rituximab therapy for idiopathic MN (IMN) in the Asian population. We present the cases of three IMN patients who were treated with single-dose rituximab after they showed no response to conventional therapies, including corticosteroids, cyclosporine, cyclophosphamide, mizoribine, and mycophenolate mofetil. Although one case showed no response, a complete or incomplete remission was achieved in the other two cases. Rituximab may therefore be a beneficial treatment option for IMN.

Original languageEnglish
Pages (from-to)1679-1686
Number of pages8
JournalInternal Medicine
Volume56
Issue number13
DOIs
Publication statusPublished - 2017
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Single-dose rituximab therapy for refractory idiopathic membranous nephropathy: A single-center experience'. Together they form a unique fingerprint.

Cite this